Teva Pharmaceutical Industries has reported encouraging results from a three-year study evaluating relapsing-remitting multiple sclerosis patients who failed first-line monotherapy and switched treatments.
The results demonstrated that patients who switched from interferon beta (IFN
beta) to Copaxone (glatiramer acetate injection) experienced a 77% reduction in
annualized relapse rates (0.63 to 0.14). In addition, these patients did not
progress significantly in their disability as measured by expanded disability
status scale (EDSS).